Oestrogen is bad for patients with breast cancer? by Jordan, V Craig et al.
Breast cancer is a hormone-dependent disease, and a
proportion of patients with oestrogen receptors (ERs) will
respond to ovarian ablation [1-3]. For this reason, oestrogen is
considered bad for patients with breast cancer. This short
communication presents our evolving understanding of
oestrogen’s role as a survival signal in breast cancer and new
emerging knowledge of the apoptotic actions of oestrogen [4].
Synthetic oestrogens based either on the structure of
triphenylethylene or the very potent but shorter acting
diethylstilboestrol [5,6] were described more than 60 years
ago. This proved to be a cheap source of new medicines.
High-dose synthetic oestrogen administration was found to
be effective in the treatment of breast and prostate cancer
[7], but low-dose synthetic oestrogens never really became
accepted as hormone replacement therapy in postmeno-
pausal women. Indeed, diethylstilboestrol subsequently
achieved notoriety as an oestrogen supplement to prevent
recurrent abortion. Children of treated mothers had a high
incidence of clear cell carcinoma of the vagina [8,9]. In
contrast, the synthetic oestrogens based on triphenyl-
ethylenes were subsequently to undergo a metamorphosis
and be transformed into anti-oestrogens used for the treat-
ment of breast cancer [10].
Based on the link identified between oestrogen and the
development and growth of some breast cancers, the current
strategy for the treatment and prevention of ER-positive
breast cancer is the application of long-term antihormonal
therapy [11]. The use of long-term tamoxifen therapy [12] has
had a profound effect on survival, but in addition the wide
distribution of tamoxifen has resulted in a declining death rate
from breast cancer over the past few years. Currently, the
aromatase inhibitors [13-15] are proving to represent a
modest improvement over tamoxifen therapy, especially for
the postmenopausal woman with concerns about endometrial
cancer and blood clots. However, tamoxifen remains the
treatment of choice for the premenopausal woman with ER-
positive breast cancer.
The past 30 years have seen dramatic advances in the
practical prospects for the chemoprevention of breast cancer.
Studies in the laboratory with tamoxifen [16,17] and raloxifene
[18,19] have now translated into clinical practice for either
chemoprevention of breast cancer in high-risk women with
tamoxifen [20,21] or treatment of osteoporosis with prevention
of breast cancer with raloxifene [22,23]. However, widespread
use of long-term antihormonal therapies for the treatment and
prevention of breast cancer creates consequences for the
tumour in the form of antihormonal drug resistance. Never-
theless, laboratory study of antihormonal drug resistance has
revealed an unanticipated vulnerability of breast cancer cells.
It has been known for about 20 years that long-term oestro-
gen treatment of athymic mice inoculated with the ER-
positive breast cancer cell line MCF7 will result in trans-
plantable ER-positive tumours [24]. Tamoxifen will initially
prevent tumour growth, but long-term tamoxifen therapy
causes tumours to become drug-resistant, which is expres-
sed as tamoxifen-stimulated growth [25]. This model system
replicates the clinical situation for the treatment of advanced
breast cancer, and second-line therapies in the clinic are
usually an aromatase inhibitor or the pure anti-oestrogen
fulvestrant [26,27]. However, the process of developing
tamoxifen-stimulated tumour growth in the laboratory, which
takes 1 to 2 years, does not replicate adjuvant therapy with
tamoxifen, which has a duration of 5 years. To address this
issue, tamoxifen-stimulated tumours were serially trans-
planted into successive generations of athymic mice and a
novel form of drug resistance was recognized. Tamoxifen and
other selective ER modulators (SERMs) such as raloxifene
stimulate tumour growth [28], but remarkably oestrogen now
does not support tumour growth but causes rapid tumour
regression [29,30].
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© 2007 BioMed Central LtdThis action of oestrogen after 5 or more years of tamoxifen
therapy demonstrates that there is an evolution of drug
resistance in breast cancer cells. This was recently classified
[31]. The early phases of drug resistance with tamoxifen are
referred to as phase I resistance. This is indicated by a tumour
growing with either tamoxifen or oestrogen treatment. In
contrast, phase II resistant tumours grow only with tamoxifen,
and oestrogen kills tumour cells. Similar studies are now being
conducted using long-term oestrogen deprivation to replicate
what will occur with the aromatase inhibitors [32].
Early studies growing MCF7 breast cancer cells in
oestrogen-free media identified increased intracellular ER
levels and spontaneous cell growth [33,34]. Several
oestrogen-independent clones were isolated for study
[35,36] and the idea was proposed that MCF7 cells are
hypersensitized to grow in extremely low levels of oestrogen
(below the level that can be detected or further reduced)
[37]. However, Song and coworkers [38] observed that
increasing concentrations of oestradiol could increase
apoptosis in oestrogen-deprived cells by increasing the
concentration of Fas ligand that activates death receptor
pathways. Thus, the original observations that phase II
tamoxifen resistant tumours could be treated with
physiological oestrogen [29,30] were extended to aromatase
inhibitor resistant cells. However, in contrast to the study
conducted by Song and coworkers [38], phase II tamoxifen
resistant tumours respond to increasing oestrogen treatment
by increasing the Fas receptor, and decreasing HER2/neu
and nuclear factor-κ, which is associated with tumour
regression [39]. Furthermore, MCF7 cells kept for many years
under oestrogen-depleted conditions using medium contain-
ing stripped foetal bovine serum produce rapid apoptosis via
an intrinsic mechanism directed at the mitochondrion [40,41].
However, both Lewis and coworkers [41] and Song and
Santen [42] found that apoptosis is modulated through bcl-2
or bcl-2XL.
It is also perhaps important to note that the new knowledge
about oestrogen action emerged through re-examination of
existing cell lines. In early reports on the effects of oestrogen
withdrawal, no oestrogen-induced apoptosis was noted
[35,36], but by altering culture conditions or extending the
period of oestrogen exposure, apoptosis occurs [40,41,43].
Overall, the phenomenon observed with long term oestrogen
withdrawal is similar to the phase II resistance of the model
described for SERMs [32].
Lonning and coworkers [44] addressed the hypothesis that
patients with ER-positive breast cancers who have been
treated exhaustively with antihormonal therapy could
potentially respond to high-dose oestrogen therapy. Thirty-
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Figure 1
Organization of Department of Defense Center of Excellence Grant. Shown is the organization of our Department of Defense Center of Excellence
Grant entitled ‘A new therapeutic paradigm for breast cancer exploiting low-dose oestrogen-induced apoptosis’. The model systems to study the
survival and apoptosis induced with oestrogen are being used in time course experiments at the Fox Chase Cancer Center. The materials are
distributed to Translational Genomics for genomic analysis using comparative genomic hybridization, small interfering (si)RNA analysis or Agilent
gene array analysis, and the Vincent T Lombardi Cancer Center is involved in conducting proteomics analysis. All results are uploaded into a
shared secure web for data processing and target identification by our informatics and biostatistical group. Each laboratory is able to validate
emerging pathways and study individual genes of interest. Our programme is integrated with a clinical trials programme that provides patient
samples for validation of apoptotic or survival pathways. We are grateful to our external advisory board of patient advocates and professional
colleagues for their continuing advice and support.two patients with advanced breast cancer previously exposed
to between two and ten (median four) endocrine treatments
were treated with diethylstilboestrol 5 mg three times daily.
Therapy was well tolerated but four patients terminated
treatment within 2 weeks of starting and another two stopped
treatment before progression. One of these patients had
stable disease for 15 weeks and one a partial response for
39 weeks. Of the remainder, four patients obtained a
complete response and six patients a partial response. Two
patients had stable disease for 6 months and one for more
than 1 year. Overall, these extremely encouraging preliminary
studies with high-dose oestrogen therapy are complemented
by anecdotal reports of the effectiveness of low-dose
oestrogen treatment for those women with endocrine
refractory breast cancer after exhaustive antihormonal therapy
(Ingle J, Dixon M, personal communication). As a result,
several clinical studies are currently underway (Ellis M,
Santen R, personal communications).
Based on preclinical laboratory modelling, we have translated
the new biology of oestrogen action into a Department of
Defense Center of Excellence grant with laboratory and
clinical collaborators illustrated in Figure 1. Our goal is to
define the pathways for oestrogen-induced survival and
apoptosis in endocrine responsive breast and endometrial
cancer, and to use the emerging database to guide the
interpretation and development of a series of clinical trials.
The ultimate goal of our clinical trial design is illustrated in
Figure 2 and currently consists of two separate but
interconnected therapeutic oestrogen studies, designed to
determine the lowest dose of a 12-week course of oestrogen
that causes a positive therapeutic effect.
In summary, the development and extensive clinical applica-
tion of long-term antihormonal therapy [11] has had conse-
quences for the patient with the development of antihormonal
drug resistance in some breast cancers [31]. However, with
the development of drug resistance to exhaustive anti-
hormonal therapy, a vulnerability of the cancer has been
exposed. The recognition of the new biology of oestrogen
action that causes apoptosis in sensitive breast tumours now
opens an unanticipated door of opportunity to exploit the
findings to aid patients. Although the actual clinical respon-
ses may not be profound in unselected patient populations or
in populations whose tumours do not have the correct (stage
II) form of breast cancer drug resistance, our ability to
decipher apoptotic mechanisms from laboratory models, and
eventually to target patients appropriately, may have profound
and positive effects for some patients. The translational
knowledge gained over the coming few years may again
provide unanticipated opportunities to exploit the discovery of
‘apoptotic triggers’ for other forms of cancer.
It is perhaps pertinent to restate that for 70 years there has
been an ‘ebb and flow’ relationship for the role of oestrogen
in breast tumour homeostasis. We have illustrated in this
article many of the changing fashions that have occurred in
the perception of oestrogen as either hero or villain with
repect to women’s health. The effects of modulating the ER
system in the breast, at one time or another, have been
dismissed because the effects are small or believed to be of
no major consequence. Nevertheless, the number of events
becomes accumulative. By way of example, it is important to
recall that initial use of tamoxifen, a failed contraceptive, to
treat unselected populations yielded only modest responses
for some patients with metastatic breast cancer [45]. Years
later, after deciphering the target populations and translating
the appropriate treatment strategies from the laboratory to
the clinic, the drug became the ‘gold standard’ for endocrine
therapy [45] and was credited with improving the survival of
hundreds of thousands of women [12]. The challenge for the
future is to exploit the profound apoptotic action of oestradiol
as a lead to develop innovative new therapies for cancer.
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Figure 2
Anticipated treatment plan for third-line endocrine therapy. Patients
must have responded and failed two successive antihormonal
therapies to be eligible for a course of low-dose oestradiol therapy for
3 months. The anticipated response rate is 30% [44] and responding
patients will be treated with anastrozole until relapse. Validation of the
treatment plan via the Center of Excellence Grant (Figure 1) will
establish a platform to enhance response rates with apoptotic
oestrogen by integrating known inhibitors of tumour survival pathways
into the 3-month low-dose oestrogen debulking treatment plan. The
overall goal is to increase response rates and maintain patients for
longer on antihormonal strategies before chemotherapy is required.Breast Cancer Research    Vol 9 Suppl 2 Jordan et al.
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